Skip to main content
Iterum Therapeutics plc logo

Iterum Therapeutics plc — Investor Relations & Filings

Ticker · ITRM ISIN · IE000TTOOBX0 US Manufacturing
Open in API
Filings indexed 506 across all filing types
Latest filing 2018-04-10 Regulatory Filings
Country US United States of America
Listing US ITRM

About Iterum Therapeutics plc

https://www.iterumtx.com/

Iterum Therapeutics plc is a pharmaceutical company focused on developing and commercializing differentiated anti-infectives to combat multi-drug resistant (MDR) pathogens. The company's lead product is sulopenem, a novel penem anti-infective compound developed in both oral and intravenous (IV) formulations. The oral formulation, ORLYNVAH™, has received U.S. FDA approval for the treatment of uncomplicated urinary tract infections (uUTIs) in adult women caused by designated susceptible microorganisms. ORLYNVAH™ is the first oral penem antibiotic approved in the United States, addressing the need for new treatment options against the growing threat of antibiotic-resistant bacteria.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2018
Regulatory Filings Classification · 80% confidence The provided document text appears to be an encoded or binary file content (e.g., base64 or uuencoded data) rather than readable text. There are no discernible keywords, regulatory headers, form names, fiscal period dates, or document titles that indicate the nature of the filing. The document length is 15,000 characters, which is substantial, but without readable content or metadata indicating the type, it is impossible to classify it as a specific report type such as Annual Report (10-K), Interim Report (IR), Earnings Release (ER), or others. Given the lack of identifiable information and the fallback rule, the appropriate classification is Regulatory Filings (RNS), which serves as a catch-all for filings that do not fit other categories.
2018-04-10 English
Regulatory Filings 2018
Regulatory Filings Classification · 100% confidence The document is a letter addressed to the U.S. Securities and Exchange Commission (SEC) responding to comments on a Draft Registration Statement on Form S-1. It discusses amendments to the Form S-1 registration statement, addressing SEC staff comments and revising disclosures accordingly. The Form S-1 is a registration statement filed by companies planning an initial public offering (IPO) or other securities offering. This document is not a financial report, earnings release, or other typical corporate filing but rather a regulatory correspondence related to the registration process. Therefore, it fits best under the category of Regulatory Filings (RNS), which includes general regulatory announcements and compliance documents that do not fit other specific categories.
2018-03-28 English
Capital/Financing Update 2018
Capital/Financing Update Classification · 100% confidence The document is a Form S-1 Registration Statement filed with the U.S. Securities and Exchange Commission (SEC) for Iterum Therapeutics plc. It is a registration statement under the Securities Act of 1933, used for initial public offerings (IPOs) or other securities offerings. The text includes detailed prospectus information, risk factors, business overview, management discussion, financial data, and underwriting details. This type of filing is related to capital raising and securities registration, not an annual report, earnings release, or other financial report. Therefore, it fits the category of Capital/Financing Update (CAP).
2018-03-28 English
Regulatory Filings 2018
Regulatory Filings Classification · 100% confidence The document is a detailed response letter from Iterum Therapeutics Ltd. to the U.S. Securities and Exchange Commission (SEC) staff regarding comments on their Draft Registration Statement on Form S-1. The letter addresses specific SEC comments on disclosures, clinical trial data, accounting policies, and other regulatory requirements related to the company's proposed initial public offering (IPO). The presence of references to Form S-1, detailed responses to SEC comment letters, and the nature of the content indicate this is a regulatory filing related to the registration statement process for an IPO. This type of document is best classified under Regulatory Filings (RNS), as it is a formal communication with the SEC addressing regulatory comments and not a financial report, earnings release, or other specific report type.
2018-03-09 English
Capital/Financing Update 2018
Capital/Financing Update Classification · 100% confidence The document is a Form S-1 Registration Statement filed with the U.S. Securities and Exchange Commission. It is a registration statement under the Securities Act of 1933 for an initial public offering (IPO) of ordinary shares by Iterum Therapeutics Limited. The text includes detailed information about the offering, company overview, risk factors, use of proceeds, management discussion, and other sections typical of an IPO prospectus. This type of filing is a capital markets document related to fundraising and securities issuance, not a financial report, earnings release, or management report. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is substantial and contains detailed offering information, confirming it is not a brief announcement or a report publication notice.
2018-03-09 English
Regulatory Filings 2018
Regulatory Filings
2018-03-02 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.